Skip to content


Oxbryta (voxelotor) is a small molecule pharmaceutical. Voxelotor was first approved as Oxbryta on 2019-11-25. It is used to treat sickle cell anemia in the USA. It is known to target cytochrome P450 2C8, cytochrome P450 3A4, and cytochrome P450 2C9. Oxbryta's patents are valid until 2037-10-12 (FDA).
Trade Name Oxbryta
Common Name Voxelotor
Indication sickle cell anemia
Drug Class
Get full access now